Search

Chemotherapy is a common treatment for acute myeloid leukemia, but patients often stop responding. Until now, not much was known about why.

… Friday, December 2, 2016 Summary Acute myeloid leukemia is usually treated with chemotherapy , but patients often stop responding to these drugs and develop resistance to them. Now MSK investigators are learning why that is the case. Highlights Acute myeloid leukemia is the most common acute leukemia

Even as a child, physician-scientist Veronica Rotemberg always knew that her future self would be wearing a lab coat. Learn more about her journey and research.

… Monday, April 29, 2024 Veronica Rotemberg, MD, PhD , Director of Dermatology Informatics Program at Memorial Sloan Kettering Cancer Center (MSK), and leader of her own lab at Memorial Hospital, is passionate about her patients, technology, and the future. She has been a member of the MSK faculty for

New research from Sloan Kettering Institute investigators pinpoints altered cell metabolism as a cause of B cell lymphoma.

… Monday, June 22, 2020 Summary Scientists at the Sloan Kettering Institute have found that increased activity of a normal metabolic enzyme can lead to cancer. The enzyme, SHMT2, is a driver of a large portion of B cell lymphomas and could be a potential drug target. Because of how aggressively they divide

Research from investigators at the Sloan Kettering Institute shows how a brain circuit controls mating behavior in fruit flies.

… Thursday, June 25, 2020 Summary Sloan Kettering Institute scientists have discovered how a genetic switch in the brain controls mating behavior in female fruit flies. The insights contribute to scientists’ understanding of fundamental neurobiological processes, including those that may go awry in disease

Get tips from a Memorial Sloan Kettering dietitian if you’ve completely lost your appetite during cancer treatment.

… Thursday, October 17, 2019 Summary A Memorial Sloan Kettering expert offers strategies to help people with cancer who feel like they can’t eat anything. In the Kitchen CancerSmart: In the Kitchen with MSK Learn more Getting proper nutrition during cancer treatment is vital. As the body tries to cope

… Thursday, April 6, 2023 Memorial Sloan Kettering Cancer Center (MSK) researchers have discovered that innate immune signaling drives late cardiac toxicity after DNA-damaging cancer therapies. Their results, published in the Journal of Experimental Medicine on March 6, 2023, identify a targetable mechanism

June’s “MSK Science Spotlight” segments kick off on Monday, June 1, featuring the honoree of the Katharine Berkan Judd Award Lectureship, Ron Vale, PhD, Vice President and Executive Director, Janelia Research Campus at the Howard Hughes Medical Institute.

… Monday, June 1, 2020 June’s “ MSK Science Spotlight ” segments kick off on Monday, June 1, featuring the honoree of the Katharine Berkan Judd Award Lectureship, Ron Vale, PhD, Vice President and Executive Director, Janelia Research Campus at the Howard Hughes Medical Institute. Dr. Vale will be presenting

Metastasis remains the primary challenge to reducing cancer deaths worldwide. A new MSK study is providing unique insights that researchers say point to new therapeutic opportunities.

… Wednesday, October 30, 2024 Metastasis remains the primary challenge to reducing cancer deaths worldwide, says Memorial Sloan Kettering Cancer Center (MSK) gastrointestinal oncologist Karuna Ganesh, MD, PhD .  That’s when a primary tumor — colorectal cancer, for example — spreads to a new part of the

The historic clinical trial is a global effort between Obafemi Awolowo University, Lagos University Teaching Hospital, and Medserve in Nigeria and Memorial Sloan Kettering Cancer Center in the United States.

… Wednesday, February 4, 2026 A ground-breaking clinical trial aimed at transforming treatment options for patients with colorectal cancer in Nigeria is actively enrolling patients after gaining official approval by the National Health Research Ethics Committee (NHREC) and the National Agency for Food

Memorial Sloan Kettering researchers are studying how drugs that reverse malfunctioning proteins may treat disease.

… Tuesday, August 3, 2021 Sloan Kettering Institute scientist Gabriela Chiosis , a member of the Chemical Biology Program , has devoted her research to studying how proteins take shape and interact with each other and how it can lead to disease when these proteins go awry. On August 3, 2021, she published